TDF/FTC

DRUG6 trials

Conditions

Behavior and Behavior MechanismsGenderHIVHIV PreventionHIV-1 InfectionsHIV/AIDSInfection, Human Immunodeficiency VirusInfection, Human Immunodeficiency Virus I

Phase 1

Transgender Youth and PrEP: PK, Safety, Uptake & Adherence - PK Study

CompletedNCT03652623

Hektoen Institute for Medical ResearchBehavior and Behavior Mechanisms, Gender, HIV/AIDS

Start: 2018-07-23End: 2023-11-30Updated: 2024-04-01

Phase 2

Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults

TerminatedNCT02415595

ViiV HealthcareInfection, Human Immunodeficiency Virus

Start: 2015-05-12End: 2017-08-21Updated: 2018-09-19

Phase 3

A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily

CompletedNCT01227824

ViiV HealthcareInfection, Human Immunodeficiency Virus I

Start: 2010-10-19End: 2016-12-27Updated: 2018-10-09

Expanded PrEP Implementation in Communities in NSW

CompletedNCT02870790

Kirby InstituteHIV, STI

Start: 2016-03-31End: 2020-10-31Updated: 2021-02-17

Phase 4

HIV PrEP Priming of Immune Effectors

NCT02593409

MRC/UVRI and LSHTM Uganda Research UnitHIV-1 Infections

Start: 2017-05-25End: 2018-06-30Target: 220Updated: 2017-09-19

Unknown Phase

A Pharmacist-run PrEP Program for Women

TerminatedNCT05755204

Orlando Immunology CenterHIV Prevention

Start: 2023-06-21End: 2024-10-15Updated: 2025-02-14

AIDS Research and Human Retroviruses2022-08-0911 citations

Gender-Affirming Hormone Pharmacokinetics Among Adolescent and Young Adult Transgender Persons Receiving Daily Emtricitabine/Tenofovir Disoproxil Fumarate

AIDS Research and Human Retroviruses2022-07-1115 citations

Low Prior Exposure and Incidence of Hepatitis C in Human Immunodeficiency Virus–Negative Gay and Bisexual Men Taking Preexposure Prophylaxis (PrEP): Findings From the Expanded PrEP Implementation in Communities–New South Wales Prospective Implementation Study

Clinical Infectious Diseases2022-03-245 citations

Long-term protection from HIV infection with oral HIV pre-exposure prophylaxis in gay and bisexual men: findings from the expanded and extended EPIC-NSW prospective implementation study.

2021-07-0173 citations

Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HIV-1-infected adults: Week 24 primary analysis from a randomized Phase IIb trial

PLoS ONE2018-10-2343 citations

Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study.

2018-10-17261 citations

Expanded HIV pre-exposure prophylaxis (PrEP) implementation in communities in New South Wales, Australia (EPIC-NSW): design of an open label, single arm implementation trial.

2018-02-0234 citations

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study.

2013-01-08418 citations